ProfileGDS5678 / 1453338_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 87% 88% 85% 88% 93% 92% 89% 88% 90% 90% 90% 88% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0169389
GSM967853U87-EV human glioblastoma xenograft - Control 26.7430587
GSM967854U87-EV human glioblastoma xenograft - Control 36.9123988
GSM967855U87-EV human glioblastoma xenograft - Control 46.5805885
GSM967856U87-EV human glioblastoma xenograft - Control 56.8621488
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6223293
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4765392
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.961489
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.847688
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.219690
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2146490
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2025690
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9247588
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3759491